

## REMARKS

The Examiner required restriction under 35 U.S.C. § 121 between the following groups:

Group I: claims 29 to 47, allegedly drawn to an antibody that specifically binds human calcium independent cytosolic phospholipase A<sub>2</sub>/B enzyme, and compositions containing said enzyme, classified in class 424, subclass 146.1; and

Group II: claims 48 to 55, allegedly drawn to an antibody that specifically binds hamster calcium independent cytosolic phospholipase A<sub>2</sub>/B enzyme, and compositions containing said enzyme, classified in class 424, subclass 139.1.

Action at page 2. Applicants elect to prosecute Group I, claims 29-47, which the Examiner alleges are drawn to an antibody that specifically binds human calcium independent cytosolic phospholipase A<sub>2</sub>/B enzyme, and compositions containing said enzyme.

The Examiner also required an election of a single disclosed species among allegedly distinct species selected from SEQ ID NO: 17 (SEQ ID NO: 16), SEQ ID NO: 19 (SEQ ID NO: 18), SEQ ID NO: 21 (SEQ ID NO: 20), and SEQ ID NO: 23 (SEQ ID NO: 22).

Applicants elect the species SEQ ID NO: 19 (SEQ ID NO: 18). Claims 29, 31, 32, and 37-47 encompass the elected species.

Applicants respectfully remind the Examiner that, in the event that the elected species is found allowable, the Examiner is required to examine the claims with respect to the non-elected species. See MPEP §809.02(c)(B)(1).

Please grant any extensions of time required to enter this Response and charge any additional required fees to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: December 1, 2004

By: \_\_\_\_\_



Rebecca B. Scarr  
Reg. No. 47,057